Mirabegrón Alter (Mirabegron)

Mirabegron, the active ingredient in Mirabegrón Alter, is a β3‑adrenergic receptor agonist presented as an oral formulation for prescription use. It is indicated for the management of overactive bladder symptoms, including urinary urgency, frequency and urge incontinence, in adult patients.

GNH USA supplies Mirabegrón Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑approved batches to global markets.

Mirabegron is used to treat conditions within the overactive bladder disease family, improving bladder storage function.

- Overactive bladder: increases bladder capacity and reduces urgency episodes. - Urinary urgency: lessens the sudden need to void. - Urinary frequency: decreases the number of daytime voids. - Urge urinary incontinence: reduces involuntary leakage episodes.

Adverse reactions reported with mirabegron can be grouped by frequency.

Common Side Effects: - Hypertension: mild to moderate increase in blood pressure. - Nasopharyngitis: inflammation of the nasal passages and throat. - Urinary tract infection: symptoms of dysuria or frequency. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Severe hypertension: marked elevation of blood pressure requiring medical intervention. - Angioedema: swelling of face, lips, or airway. - Tachycardia: rapid heart rate. - Allergic reactions: rash, pruritus, or anaphylaxis.

When prescribing mirabegron, clinicians should consider several safety measures.

- Blood pressure monitoring: check baseline and periodically during therapy. - Renal function assessment: evaluate in patients with moderate to severe impairment. - Concomitant antihypertensive review: adjust doses if additive blood pressure‑lowering occurs. - Elderly caution: start at lower dose and monitor for orthostatic effects. - Avoid use in uncontrolled hypertension: contraindicated. - Store at ambient temperature: keep in original packaging, protect from moisture.

Mirabegron may affect the plasma levels of other medicines through enzyme modulation.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise plasma concentrations. - Other β3‑adrenergic agonists: additive pharmacologic effects.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance risk of hypotension. - Antimuscarinic bladder agents (e.g., oxybutynin): monitor for synergistic urinary effects. - NSAIDs: assess renal function when combined with mirabegron.